Replies to post #101670 on Biotech Values

[ThomasS]

MNTA: "MNTA coming out and explicitly noting that they expect to fully reimburse Sandoz in 3 quarters is also a new tidbit of information."

The stock should've risen on that tidbit, imo.

[jbog]

Mpower,

It was known that Momenta would have to reimburse Sandoz as follows:

a portion of the development expenses and certain legal expenses which have exceeded a specified amount will be offset against the profit-sharing amounts and royalties payments. The portion of these expenses we are obligated to reimburse to Sandoz varies depending on whether we are entitled to profit-sharing amounts or royalties payments and is proportional to our economic interest in sales of enoxaparin sodium injection by Sandoz.

To this day we do not know the value of these expenses are because for some reason they are not defined.

Everyone here believes Momenta stock is a steal at these prices, yet there are insiders that are selling as recently as last week in the $17's. Of course we can come up with reasons why they are selling, but the fact is they are selling. Keep in mind, that any of the 'tax reasons' wouldn't be due until mid Sept..

Time will tell.